Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.O)

SPPI.O on Nasdaq

3.91USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$3.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
835,487
52-wk High
$7.74
52-wk Low
$3.21

Select another date:

Fri, Nov 18 2016

Spectrum Pharma says FDA rejects its bladder cancer drug

Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker's bladder cancer treatment, apaziquone.

UPDATE 1-Spectrum Pharma says U.S. FDA rejects its bladder cancer drug

Nov 18 Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker's bladder cancer treatment, apaziquone.

BRIEF-Spectrum Pharma receives complete response letter from FDA for Qapzola

* Spectrum Pharmaceuticals Inc says on November 15, 2016, company met with FDA to discuss strategy for further development of Qapzola

Spectrum Pharma says U.S. FDA rejects its bladder cancer drug

Nov 18 Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration rejected the drugmaker's bladder cancer treatment.

BRIEF-Spectrum pharmaceuticals posts Q3 loss per share of $0.22

* Spectrum Pharmaceuticals Inc says total product sales were $30.3 million in Q3 of 2016

Spectrum bladder cancer drug not effective: U.S. FDA panel

Spectrum Pharmaceuticals Inc's experimental bladder cancer treatment apaziquone is not effective in delaying the time to recurrence of the disease, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday.

Spectrum bladder cancer drug not effective - U.S. FDA panel

Sept 14 Spectrum Pharmaceuticals Inc's experimental bladder cancer treatment apaziquone is not effective in delaying the time to recurrence of the disease, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday.

BRIEF-Spectrum Pharmaceuticals says PDUFA date set for Qapzola NDA is Dec. 11

* FDA advisory committee votes that Qapzola (apaziquone) has not shown substantial evidence of a treatment effect over placebo

BRIEF-Spectrum Pharma Q2 non-gaap loss per share $0.05

* Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S

BRIEF-Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation

* Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn

Select another date: